Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2011-07-12
2011-07-12
Davis, Ruth (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
Reexamination Certificate
active
07976837
ABSTRACT:
The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well as a pharmaceutical composition therefore. Namely, the present invention relates to a method of preventing and treating cerebral infarction by activating PAR-2 and/or promoting expression of PAR-2 gene. The present invention further relates to a pharmaceutical composition for preventing and treating cerebral infarction, comprising one, or two or more of the active ingredients selected from the group consisting of a PAR-2 activator and/or a PAR-2 gene expression promoter; as well as a pharmaceutically acceptable carrier. It further relates to a method of screening an active ingredient for preventing and treating cerebral infarction using as an indicator the PAR-2 activation promoted by a test substance.
REFERENCES:
patent: 6124291 (2000-09-01), Berryman et al.
patent: 99/50254 (1999-10-01), None
patent: 2004/080373 (2004-09-01), None
Supplementary European Search Report dated Jul. 17, 2009 issued in corresponding European Application No. 05751580.1.
Mayer, S. A., “Intracerebral Hemorrhage: Natural History and Rationale of Ultra-Early Hemostatic Therapy”, Intensive Care Medicine, Oct. 2002, pp. S235-S240, vol. 28.
Wang, J. et al., “Up-regulation and Activation of Proteinase-Activated Receptor 2 in Early and Delayed Radiation Injury in the Rat Intestine: Influence of Biological Activators Proteinase-Activated Receptor 2”, Radiation Research, Nov. 1, 2003, pp. 524-535, vol. 160, No. 5.
Al-Ani, B., et al., “Proteinase-Activated Receptor-2: Key Role of Amino-Terminal Dipeptide Residues of the Tethered Ligand for Receptor Activation”, Molecular Pharmacology, Jan. 2004, pp. 149-156, vol. 65, No. 1.
Milia, A. F., “Protease-Activated Receptor-2 Stimulates Angiogenesis and Accelerates Hemodynamic Recovery in a Mouse Model of Hindlimb Ischemia”, Circulation Research, Aug. 23, 2002, pp. 346-352, vol. 91, No. 4.
Valeria S. Ossovskaya et al., “Protease-Activated Receptors: Contribution to Physiology and Disease”, Physiological Reviews, vol. 84, pp. 579-621, 2004, The American Physiological Society, Maryland, USA.
Scott R. Macfarlane et al., “Proteinase-Activated Receptors”, Pharmacology Reviews 53, pp. 245-282, 2001, The American Society for Pharmacology and Experimental Therapeutics, USA.
Sverker Nystedt et al., “Molecular cloning of a potential proteinase activated receptor”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9208-9212, 1994, Cornell University Medical College, NY, USA.
Virginia L. Smith-Swintosky et al., “Protease-Activated Receptor-2 (PAR-2) Is present in the Rat Hippocampus and Is Associated with Neurodegeneration”, Journal of Neurochemistry, vol. 69, pp. 1890-1896, 1997, Lippincott-Raven Publishers, Philadelphia, USA.
Frank Striggow et al., “Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia”, European Journal of Neuroscience, vol. 14, pp. 595-608, 2001, Federation of European Neuroscience Societies.
E. Sander Connolly et al., “Procedural and Strain-related Variables Significantly Affect Outcome in a Murine Model of Focal Cerebral Ischemia”, Neurosurgery, vol. 38, pp. 523-532, 1996, Columbia University, College of Physicians and Surgeons, NY, USA.
Marina Molino et al., “Endothelial Cell Thrombin Receptors and PAR-2”, The Journal of Biological Chemistry, vol. 272, pp. 11133-11141, Apr. 25, 1997, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Wuyi Kong et al., “Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 8884-8889, 1997, The National Academy of Sciences, USA.
Bahjat Al-Ani et al., “Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle”, Canadian Journal of Physiology and Pharmacology., vol. 73, pp. 1203-1207, 1995, Canada.
Atsufumi Kawabata et al., “Activation of Protease-Activated Receptor-2 (PAR-2) Triggers Mucin Secretion in the Rat Sublingual Gland”, Biochemical and Biophysical Research Communications, vol. 270, pp. 298-302, 2000, Academic Press, Japan.
Sobey, C. G. et al.; “Evidence for Selective Effects of Chronic Hypertension on Cerebral Artery Vasodilatation to Protease-Activated Receptor-2 Activation”; Stroke; A Journal of Cerebral Circulation Sep. 1999 LNKD-PUBMED: 10471447, vol. 30, No. 9, Sep. 1999, pp. 1933-1940: di, ISSN: 0039-2499.
European Communication pursuant to Article 94(3) EPC dated Jun. 25, 2010, issued in European Patent Application No. 05751580.1.
Guang Jin et al.; “Deficiency of PAR-2 gene increases acute focal ischemic brain injury”; Journal of Cerebral Blood Flow & Metabolism, vol. 25, pp. 302-313, 2005. Cited in the int'l. search report.
G. S. Cottrell et al.; “Protease-activated receptor 2: activation, signalling and function”; Biochemical Society Transactions, vol. 31, part 6, pp. 1191-1197. Cited in the int'l. search report.
M. Steinhoff et al.; “Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism”; Nature Medicine, vol. 6, No. 2, pp. 151-158, Feb. 2000. Cited in the int'l. search report.
S. R. MacFarlane et al.; “Proteinase-Activated Receptors”; Pharmacological Reviews, vol. 53, No. 2, pp. 245-282, 2001. Cited in the int'l. search report.
Ahamad Hassan et al.; “Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis”, Brain, vol. 126, pp. 424-432, 2003. Cited in the int'l. search report.
International Search Report of PCT/JP2005/011122, date of mailing Aug. 30, 2005.
International Preliminary Report on Patentability dated Feb. 22, 2007, issued in corresponding PCT/JP2005/011122, with Form PCT/IB/338.
Abe Koji
Kawagoe Junichi
Davis Ruth
Kowa Company Ltd.
Westerman Hattori Daniels & Adrian LLP
LandOfFree
Method of preventing and treating brain infarction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing and treating brain infarction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing and treating brain infarction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729930